BETA: Please send your feedback!
AbbVie
ABBV:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—
About
Pharmaceuticals: Major
Founded 2013
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.
website
Headquarters
Executives
| Name | Title | Gender |
| Laura J. Schumacher | Secretary, EVP-External Affairs & General Counsel | Female |
| Richard A. Gonzalez | Chairman & Chief Executive Officer | Male |
| Ronald O. Robison, MD | Vice President-Regulatory Affairs | Male |
| William J. Chase | Chief Financial Officer & Executive Vice President | Male |
| Azita Saleki-Gerhardt, PhD | Senior Vice President-Operations | Female |
| Michael E. Severino, MD | Chief Scientific Officer & Executive VP | Male |
| Timothy J. Richmond | Senior Vice President-Human Resources | Male |
| Liz Shea | Head-Investor Relations | Female |
Mindful Investing Summary
AbbVie - Competitors and Related Companies
How AbbVie stacks up to its peers in the Pharmaceuticals: Major industry or with competing business segments.
AbbVie
ABBV:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—
Biogen
BIIB:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2020
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—
Gilead Sciences
GILD:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2020
—
Pfizer
PFE:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—
Neurocrine Biosciences
NBIX:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—